Ethypharm
Ethypharm is a French specialty pharmaceutical company founded in 1977 that develops, manufactures, and markets essential medicines for Central Nervous System disorders (severe pain and addiction) and Hospital Injectables, operating across 68+ countries through six direct affiliates and global distributor networks.
- Company typePrivate
- Founded1977
- HeadquartersFranceau, France
- Headcount1,001–5,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Ethypharm does
Ethypharm is a French specialty pharmaceutical company founded in 1977, headquartered in Saint-Cloud, France, that designs, develops, manufactures, and commercializes essential medicines focused on two therapeutic areas: Central Nervous System (CNS) disorders — particularly severe pain and opioid addiction — and Hospital Injectables for critical care. The company operates through a vertically integrated model spanning proprietary drug delivery platforms (Flashtab, Tmask, Nanosizing, Multicaps, Transmucosal, Locktab), six manufacturing sites across France, the UK, Spain, and China, and direct commercial affiliates in six key markets (France, Germany, UK, Italy, Spain, and China), complemented by distributor and licensee networks reaching 68+ countries. The product portfolio includes morphine-based pain treatments (NM-ESLON, NM-Ediat), the digital therapeutics deprexis and vorvida (via the Ethypharm Digital Therapy SAS unit), and recent additions such as Argatroban antithrombin agents, Penthrox, and Nefopam injectable.
The business generates revenue through three primary streams: direct pharmaceutical sales through the six affiliates (85% of pharma revenue), distribution and licensing in 68+ countries (15% of pharma revenue), and Contract Development and Manufacturing Organization (CDMO) services for other pharmaceutical companies (~19% of total revenue). Group net sales reached €435 million in 2024, with 39% derived from CNS and 31% from Hospital Injectables. Customers span hospitals, ICUs, emergency medicine departments, anesthesiologists, addiction treatment providers, healthcare NGOs (MSF, MEG, IDA Foundation), and pharmaceutical partners seeking CDMO services. Pricing is institutional B2B with no public list pricing.
Ethypharm is privately held with no public listing or disclosed institutional investor ownership. The company is led by President and CEO Denis Delval (appointed October 2022), with a management team including Chief Financial Officer Foucauld Ruyant, Chief Operating Officer Guilhem Maraval, Chief Commercial Operations Officer Xavier Lasserre, Chief Scientific Affairs Officer Cecile Paillous, and Chief Legal, Ethics & Compliance Officer Roseline Joannesse. The company employs approximately 1,800 staff globally, of which roughly 1,400 are in industrial operations. Recent strategic activity has been dominated by bolt-on M&A (Altan Pharma 2021, Argatroban business 2024), geographic expansion (Italy 2021), and portfolio diversification into digital therapeutics (2021) and medical cannabis (2021 onwards).
Ethypharm firmographics
Firmographics- Name
- Ethypharm
- Legal name
- ETHYPHARM SAS
- Website
- https://ethypharm.com
- Company type
- Private
- Founded year
- 1977
- Operating status
- Operating
- Headcount range
- 1,001–5,000 employees
- Short description
- Ethypharm is a French specialty pharmaceutical company founded in 1977 that develops, manufactures, and markets essential medicines for Central Nervous System disorders (severe pain and addiction) and Hospital Injectables, operating across 68+ countries through six direct affiliates and global distributor networks.
- Ownership category
- akta.pro rank
Ethypharm industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Neurology & CNS Specialty Pharmaceuticals (HLAIACAC)
- akta.pro secondary industries
- Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), Sterile Fill-Finish & Aseptic Manufacturing CDMO (HLAGABAH)
Keywords
Where Ethypharm is headquartered
LocationHeadquarters
- HQ city
- Franceau
- HQ country
- France
- HQ region
- Europe
Offices16 records
Markets served
Ethypharm business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Personnel, Supply Chain, Technology or R&D, Marketing or Sales
Revenue model
- Pharma Sales (Direct Affiliates): 85% of pharma revenue comes from direct sales through six affiliate companies in France, Germany, UK, Italy, Spain, and China. These affiliates sell Ethypharm's CNS and hospital injectable products directly to hospitals, pharmacies, healthcare professionals, and addiction treatment providers.
- Distribution: 15% of pharma revenues come from distribution activities through a network of distributors across EMEA, North America, LATAM, and APAC.
- CDMO (Contract Development and Manufacturing): Contract Development and Manufacturing Organization activities contributing approximately 19% of revenue through partnerships with other pharmaceutical companies, providing flexible development and manufacturing solutions for small molecule APIs, advanced intermediates, oral solid dosage forms, and injectable products.
Go-to-market motion1 record
Distribution channels4 records
Marketing channels5 records
Ethypharm product offering
Product offeringCore offering
Ethypharm designs, formulates, develops, manufactures, and markets specialty pharmaceutical products centered on Central Nervous System (CNS) disorders (severe pain and addiction treatment) and Hospital Injectables (critical care). It also operates as a Contract Development and Manufacturing Organization (CDMO), providing development and production services to third-party pharmaceutical clients, and has begun distributing digital therapies such as deprexis and vorvida alongside its CNS portfolio.
Differentiator
Problem solved
Functional benefit
Brands
- NM-ESLON: Morphine sulfate extended release capsules for pain management
- NM-Ediat
- NOYADA
- Etiasa
- Recivit
- Argatra
- Arganova
- Novastan
- Exembol
Products and services
- NM-ESLON / NM-Ediat (morphine) Specialty morphine formulations (including orodispersible and sustained-release presentations) for severe pain management, targeted at hospital and specialist pain clinics.
- Recivit (fentanyl) Fentanyl-based specialty analgesic for severe pain, targeted at specialist prescribers and hospital settings under controlled-substance regulations.
- Argatroban portfolio (Argatra / Arganova / Novastan / Exembol) Argatroban injectable anticoagulant marketed under multiple brand names for use in critical care and interventional cardiology settings.
- Etiasa (Mesalazine) Mesalazine specialty product for inflammatory bowel disease, distributed through Ethypharm's sales affiliates and licensee network.
- NOYADA (Captopril) Captopril specialty cardiovascular product in Ethypharm's portfolio, distributed through its sales network.
- Nefopam HCl injectable Nefopam hydrochloride injectable for moderate to severe pain in hospital and perioperative settings.
- Methadone / Buprenorphine / Naloxone addiction treatments Specialty opioid-agonist and antagonist products used in opioid-dependence treatment programs, targeting addiction medicine specialists and treatment centers.
- Digital therapies (deprexis, vorvida) Digital therapeutic programs (deprexis for depression, vorvida for alcohol use disorder) distributed alongside Ethypharm's CNS portfolio to support adherence and behavioral interventions in chronic CNS conditions.
- Contract Development and Manufacturing (CDMO) services Contract development and manufacturing services offered to other pharmaceutical companies, leveraging Ethypharm's specialty manufacturing capabilities and proprietary drug delivery platforms.
Quantifiable outcome
- Operates in 68 countries worldwide
- +3 more outcomes
Companies that use Ethypharm
Customer profileNamed customers3 records
Segments4 records
Ideal customer profiles3 records
Ethypharm technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Ethypharm partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered minor and core.
- MedochemieminorLicensing agreement with Medochemie for Ethypharm Iberia to commercialise Nefopam HCl 20mg/2ml injectable solution in Spain, an analgesic for moderate to severe pain.
- Medical Developments International (MDI)coreLicensing agreement for marketing and distribution of Penthrox® (methoxyflurane), an inhaled analgesic for acute pain management, in France. Ethypharm responsible for marketing and distribution, with commercial activities expected to commence July 2025.
- Mitsubishi Tanabe Pharma Corporation (MTPC)coreAgreement to acquire the selective antithrombin agent Argatroban monohydrate (branded as Argatra®, Arganova®, Novastan®, Exembol®) in Europe from MTPC.
- HelioclimminorPartnership with French start-up Helioclim to install a reversible solar water/ammonia absorption machine incorporating internal energy storage powered by thermal solar collectors, targeting 15% reduction in electricity and gas consumption per year from 2025.
- Altan Pharma (Acquisition)coreEthypharm acquired Altan Pharma for approximately €100 million, marking entry into Spain as a fifth European country. Malin, which owned about 65% of Altan, received approximately €68 million in net proceeds. Transaction closed in H2 2021, pending regulatory approval. Altan was led by Manuel Casegas as General Manager.
- GAIA AGcoreEthypharm acquired exclusive rights for two CE-marked digital therapies: deprexis® (for depression) and vorvida® (for addiction), developed by GAIA AG. A new business unit, Ethypharm Digital Therapy SAS, was established in May 2021 to lead this initiative, with Hélène Moore appointed as Head of Digital Therapy.
- Clever LeavescoreExclusive licence agreement for sale of medical cannabis extracts in Germany, the most important European market for medical cannabis. Ethypharm positions this as a step toward becoming a leading provider of medical cannabis products in Europe.
- Aurora EuropecoreCollaboration to bring medical cannabis produced under EU GMP standards to patients in France. Aurora supplies products; Ethypharm's French subsidiary (Laboratoires Ethypharm) handles pharmaceutical distribution. One of six producer-distributor tandems selected by ANSM for the French medical cannabis pilot programme. Extended in 2023.
- ORPHELIA PharmacoreExclusive licensing agreement for the development, registration, and marketing of Kigabeq® (vigabatrin) for the first-line treatment of infantile spasms (West syndrome) in the People's Republic of China.
- Douleurs Sans FrontièrescoreActive Group strategic partnership with the NGO Douleurs Sans Frontières (Pain Without Borders) to support pain management access in underserved regions.
- Laboratoires CTRScoreExclusive partnership agreement for registration and commercialisation of Orphacol® (orphan medicine for rare inborn errors in primary bile acid synthesis) in the People's Republic of China.
- KalceksminorAgreement granting Ethypharm exclusive distribution rights in Germany for four injectable pain-management solutions in the CNS field.
Scale indicators7 records
Recent moves8 records
Expansion highlights7 records
Ethypharm competitors and assessment
Company assessmentBroad incumbents
- Catalent: Global CDMO with capabilities in sterile injectables, oral solid dose, and complex formulations. Directly comparable to Ethypharm's CDMO segment (~19% of revenue), though significantly larger in scale and scope.
- Mallinckrodt Pharmaceuticals: US-listed specialty pharmaceutical company with hospital injectables and CNS franchises. Comparable to Ethypharm across both Hospital Injectables and CNS pain/addiction, though materially larger and more US-centric.
- Endo International: US specialty pharmaceutical company with a strong pain management (including opioids) and sterile injectables franchise. Comparable to Ethypharm in CNS pain and sterile injectables, though more US-focused and currently operating under restructuring.
- Stada Arzneimittel: European specialty generics and consumer healthcare company with broad portfolio across CNS and hospital products. Comparable to Ethypharm as a privately held European specialty generics platform with M&A-driven growth.
- Almirall: European specialty pharmaceutical company focused on dermatology and CNS, with commercial presence across the same five large European markets as Ethypharm. Comparable mid-size European specialty pharma peer.
Emerging players
- Recipharm: European CDMO offering contract development and manufacturing for oral solid dose and sterile products. Comparable CDMO service portfolio to Ethypharm, particularly around small-molecule oral solids and injectables.
- Camurus: Swedish specialty pharma with proprietary drug-delivery technology (FluidCrystal) focused on CNS, opioid dependence, and pain. Comparable to Ethypharm in CNS specialization and technology-driven formulation differentiation.
Direct peers
- Grünenthal: German privately held specialty pharmaceutical company focused on pain management, including opioids and innovative non-opioid treatments. Direct competitor to Ethypharm in CNS/pain, especially across European markets.
- Indivior: Specialty pharmaceutical company focused on opioid addiction treatment (buprenorphine-based Suboxone/Sublocade) and CNS. Highly comparable to Ethypharm's addiction-treatment franchise and leadership position in the UK.
- Hikma Pharmaceuticals: Public specialty pharma with leading injectable generics and CNS franchises across MENA, Europe, and the US. Directly comparable manufacturing scale and CDMO-style injectable capabilities to Ethypharm's Hospital Injectables business.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks7 records
Key highlights7 records
Customer concentration
Ethypharm social profiles
Digital presenceEthypharm financial estimates
Financial estimateRevenue estimate
Valuation estimate
Ethypharm leadership team
Management profileNumber of profiles
Profiles3 records
Ethypharm subsidiaries and ownership
Company hierarchySubsidiaries9 records
Ethypharm funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Ethypharm M&A and investment
M&A and investmentM&A3 records
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Ethypharm
What does Ethypharm do?
Ethypharm designs, formulates, develops, manufactures, and markets specialty pharmaceutical products centered on Central Nervous System (CNS) disorders (severe pain and addiction treatment) and Hospital Injectables (critical care). It also operates as a Contract Development and Manufacturing Organization (CDMO), providing development and production services to third-party pharmaceutical clients, and has begun distributing digital therapies such as deprexis and vorvida alongside its CNS portfolio.
Is Ethypharm a public or private company?
Ethypharm is a private company. It is classified as unknown and is currently operating.
When was Ethypharm founded?
Ethypharm was founded in 1977. It employs 1,001 to 5,000 people.
Where is Ethypharm based?
Ethypharm is headquartered in Franceau, France, in the Europe region.
How does Ethypharm make money?
Three revenue lines are on record. Pharma Sales (Direct Affiliates) is the primary driver. The others are distribution and CDMO (Contract Development and Manufacturing).
Who are Ethypharm's main competitors?
Broad incumbents on record are Catalent, Mallinckrodt Pharmaceuticals, Endo International, Stada Arzneimittel and Almirall. Emerging players are Recipharm and Camurus. Direct peers are Grünenthal, Indivior and Hikma Pharmaceuticals.
Does Ethypharm have an API?
No public API is recorded for Ethypharm.
What industry is Ethypharm in?
Ethypharm's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO. Its NAICS code is 325412 and its SIC code is 2834.